![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2008, Cold Spring Harbor Laboratory Press Global histone acetylation induces functional genomic reorganization at mammalian nuclear pore complexes 1 Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA; 2 Section of Cell and Developmental Biology, Division of Biological Sciences, University of California at San Diego, La Jolla, California 92037, USA 3These authors contributed equally to this work. 4Corresponding author.E-MAIL pamela_silver/at/hms.harvard.edu; FAX (617) 432-6405. Received November 8, 2007; Accepted December 26, 2007. This article has been cited by other articles in PMC.Abstract The nuclear localization of genes is intimately tied to their transcriptional status in Saccharomyces cerevisiae, with populations of both active and silent genes interacting with components of the nuclear envelope. We investigated the relationship between the mammalian nuclear pore and the human genome by generating high-resolution, chromosome-wide binding maps of human nucleoporin 93 (Nup93) in the presence and absence of a potent histone deacetylase inhibitor (HDACI). Here, we report extensive genomic reorganization with respect to the nuclear pore following HDACI treatment, including the recruitment of promoter regions, euchromatin-rich domains, and differentially expressed genes. In addition to biochemical mapping, we visually demonstrate the physical relocalization of several genomic loci with respect to the nuclear periphery. Our studies show that inhibiting HDACs leads to significant changes in genomic organization, recruiting regions of transcriptional regulation to mammalian nuclear pore complexes. [Keywords: NPC, nucleoporin, nuclear organization, Nup93, ChIP–chip] The nucleus is a structurally and functionally complex organelle with a nonuniform interior consisting of distinct chromatin domains and several proteinaceous subcompartments. Chromosomes occupy nonrandom intranuclear positions with respect to each other and the nuclear periphery (Croft et al. 1999; Parada and Misteli 2002; Parada et al. 2002, 2004a, b; Tanabe et al. 2002a, b; Cremer et al. 2006). Chromosome positioning is believed to expose genomic loci to functionally distinct regions in the nucleus, generating transcriptional regulatory domains favoring either activation or repression. Distinct subnuclear regions also direct specific transcriptional programs by organizing genomic loci around specialized protein hubs. The nucleolus is one such region, mediating the localized transcription of ribosomal RNA genes encoded on multiple chromosomes. In the budding yeast, Saccharomyces cerevisiae, a nucleolar-proximal region has also been shown to cluster several tRNA genes (Thompson et al. 2003). Components of the nuclear envelope have been shown to assert a repressive role in transcription. In yeast, the silent mating-type loci and telomeres are regulated by components of the nuclear periphery, including the nuclear pore complex (NPC) (Stavenhagen and Zakian 1994; Thompson et al. 1994; Maillet et al. 1996; Marcand et al. 1996; Andrulis et al. 1998; Feuerbach et al. 2002). However, several recent studies have reported NPC-proximal transcriptional activation, with the concomitant recruitment of induced genes from the nuclear interior to the periphery (Brickner and Walter 2004; Casolari et al. 2004, 2005; Menon et al. 2005; Cabal et al. 2006; Dieppois et al. 2006; Drubin et al. 2006; Schmid et al. 2006; Taddei et al. 2006; Brickner et al. 2007; Luthra et al. 2007; Sarma et al. 2007). NPC association can increase the efficiency of mRNA processing and export through associations with the SAGA and TREX complexes, regulate the absolute levels of gene expression, and establish an epigenetic state that confers transcriptional memory and rapid reactivation of genes (Cabal et al. 2006; Taddei et al. 2006; Brickner et al. 2007). Furthermore, several components of the nuclear transport machinery possess boundary activity, potentially facilitating the presence of both repressive and activating domains at the nuclear periphery (Ishii et al. 2002). Elements of the nuclear periphery are also involved in transcriptional regulation in Drosophila melanogaster. In Drosophila, the dosage compensation complex (DCC), required for the twofold increase in gene expression on the peripherally localized male X chromosome, interacts with two nuclear pore components (Mendjan et al. 2006). The deletion of these pore proteins eliminates the hypertranscription of the male X chromosome, implicating Drosophila nuclear pores in transcriptional activation. In support of this, the Drosophila proteins E(y)2 and Xmas-2 were recently shown to regulate mRNA expression, export, and the subnuclear positioning of the hsp70 gene cluster (Kurshakova et al. 2007). E(y)2 and Xmas-2 are components of the Drosophila SAGA and TREX complexes, whose homologs in yeast play a role in NPC-associated transcriptional activation (Cabal et al. 2006; Dieppois et al. 2006; Taddei et al. 2006). Interestingly, a recent genome-wide study in Drosophila probing interactions between the nuclear lamina and the genome uncovered a repressive role for the nuclear periphery (Pickersgill et al. 2006). Lamins are integral components of a protein network that lines the inner surface of the nuclear envelope between NPCs and have been shown to bind chromatin in vitro. These results suggest that distinct peripheral components, NPCs, and lamins, may have divergent roles in transcriptional activation and repression, respectively. In addition, a lamin-associated protein, LAP2β, binds to histone deacetylase 3 (HDAC3), a member of a large family of proteins that removes acetyl modifications from histones (Somech et al. 2005). Highly acetylated histones are found in the promoters of transcriptionally active genes, suggesting that the lamin-mediated enrichment of HDAC3 at the nuclear periphery could aid in the maintenance of a transcriptionally repressive environment (Fukuda et al. 2006). Observations in both mouse and human cells indicate the presence of an equally diverse transcriptional regulatory domain at the nuclear periphery. For example, gene-poor chromosomes are reproducibly located near the nuclear periphery in human lymphocytes and fibroblasts (Croft et al. 1999; Boyle et al. 2001; Tanabe et al. 2002b). However, a study of the murine β-globin locus during erythroid maturation showed that significant transcriptional activity occurred at the nuclear periphery prior to the locus’s transit to the interior (Ragoczy et al. 2006). While NPCs have yet to be implicated in β-globin activation, evidence has emerged that a murine nucleoporin, Nup96, is involved in interferon gene regulation (Faria et al. 2006). The mammalian NPC is thought to contain as many as 30 unique proteins that are present in multiple copies due to the eightfold symmetry of the complex (Cronshaw et al. 2002). Nucleoporin 93 (Nup93) is a mammalian nucleoporin centrally located in the nuclear pore (Rout et al. 2000; Krull et al. 2004). siRNA-mediated depletion of Nup93 in HeLa cells resulted in misshapen nuclei lacking some, but not all nucleoporins, while depletion of both Nup93 and the transmembrane nucleoporin Ndc1 led to a complete disruption of NPCs (Mansfeld et al. 2006). Nup93, as well as importin-α and CAS (an exportin), have been shown to interact with the histone acetyltransferase (HAT), CREB-binding protein (CBP) (Ryan et al. 2006). This interaction is similar to one seen in S. cerevisiae, where association of a HAT with the NPC is mediated by interactions with SAGA, a multimeric complex required for the expression of numerous yeast genes (Green et al. 2003; Rodriguez-Navarro et al. 2004). As mentioned previously, NPC–SAGA interactions are thought to play a major role in mediating gene recruitment to the NPC in S. cerevisiae (Cabal et al. 2006; Dieppois et al. 2006; Taddei et al. 2006). HDAC inhibitors (HDACIs) globally elevate levels of histone acetylation in the nucleus by inhibiting Class I and II HDACs (Drummond et al. 2005). HDACI treatment also leads to the enrichment of acetylated histones at the nuclear periphery (Taddei et al. 2001; Gilchrist et al. 2004; Drummond et al. 2005). Local changes in genomic organization have also been reported following treatment with HDACIs (Taddei et al. 2001; Zink et al. 2004; Pickersgill et al. 2006). For example, repressed genes are no longer associated with lamins in Drosophila after treating cells with the HDACI trichostatin A (TSA) for 24 h (Pickersgill et al. 2006). In addition, the human CFTR gene moves away from the nuclear periphery upon treatment with TSA for 10 h (Zink et al. 2004). Importantly, several HDACIs are in clinical trials for various forms of cancer due to their ability to induce the expression of repressed genes that lead to growth arrest, differentiation, and apoptosis in transformed cells (Drummond et al. 2005; Glaser 2007). Disparate observations of both transcriptional activation and repression at the nuclear periphery in S. cerevisiae and Drosophila led us to investigate the presence of a similar regulatory domain in human nuclei. Using genomic location analysis (Ren et al. 2000), we report Nup93 interactions with human chromosomes 5, 7, and 16. To investigate the effects of global histone acetylation on NPC–chromatin interactions, we treated cells with TSA, a reversible HDACI that does not perturb gross nuclear structure (Taddei et al. 2001; Gilchrist et al. 2004; Pickersgill et al. 2006). Upon treatment with TSA, Nup93 distribution was significantly altered across all three chromosomes, indicative of a large-scale nuclear reorganization event with associated effects on gene expression. Analysis of Nup93-binding sites identified enrichments for several genomic features involved in transcriptional regulation. Together, these features define regions of functional interaction between the nuclear pore and the human genome. Results Identification of Nup93-binding sites We investigated Nup93–genomic association in the presence and absence of TSA, a potent HDACI. We also performed chromatin immunoprecipitation (ChIP) on several other nucleoporins including Nup62, Nup107, and Nup205, isolating significant amounts of DNA (data not shown). Nup93 was chosen for further study due to the robustness of Nup93 ChIPs and the strictly maintained subnuclear localization of Nup93 at the nuclear envelope (Fig. 1
Next, we performed genomic location analysis by coupling ChIPs and microarray analysis (ChIP–chip) to map interactions between Nup93 and the human genome. This technique has been used extensively in S. cerevisiae and is emerging as a powerful tool in higher eukaryotes (Ren et al. 2002; Carroll et al. 2005, 2006; Kim et al. 2005). Asynchronously growing HeLa S3 cells were cross-linked, stabilizing both protein–protein and protein–DNA interactions. We then performed ChIPs of Nup93 and purified, amplified, and hybridized the associated DNA to Affymetrix tiled arrays (ChipE, also referred to as chip5) containing all nonrepetitive regions of human chromosomes 5, 7, and 16. This subset of chromosomes was examined based on preliminary data obtained from Nup62, Nup107, and Nup205 genomic association studies that showed significant interactions with chromosome 7 on ENCODE arrays, including binding at the HOXA locus and CFTR (data not shown). In addition, chromosome 7 has been shown to preferentially reside near the nuclear periphery in human cells (Boyle et al. 2001). Nup93 was mapped to 207 sites on chromosomes 5, 7, and 16 in untreated cells and 170 sites in TSA-treated cells (Fig. 2A
Nup93-binding sites were mapped to their nearest neighboring gene, resulting in the assignment of 86 untreated and 90 TSA-treated genes (some genes contained multiple Nup93-binding sites) (Supplemental Table 2). The untreated gene set did not contain any enriched gene ontology groups as reported by GOstat (Beissbarth and Speed 2004). However, the TSA-treated gene set contained two enriched ontology groups: DNA-binding activity (P = 0.002) and transcription factor activity (P = 0.02). These ontology groups include several genes that are members of the HOXA transcription factor cluster on chromosome 7, a gene-dense locus with extensive Nup93 association (Fig. 2A Mapping of Nup93 sites in untreated and TSA-treated cells across chromosomes 5, 7, and 16 revealed large changes in nuclear pore association (Fig. 2A Visualization of Nup93-associated loci To verify that Nup93-binding sites were located at the nuclear periphery, we performed FISH combined with confocal microscopy to visualize the intranuclear localization of several genomic loci. Four loci with distinct Nup93 association patterns were chosen (Fig. 2B Differential Nup93 binding was also observed at the CFTR locus on the q-arm of chromosome 7. Specifically, ChIP–chip showed that Nup93 was associated with the CFTR locus in untreated cells, but was not associated with the locus in TSA-treated cells (Fig. 2A Comparison of Nup93 association in untreated and TSA-treated cells We investigated the magnitude of TSA-induced genomic reorganization and found that only 34 binding sites and 25 genes were shared between untreated and TSA-treated Nup93-binding sites, indicating a significant shift in peripheral association (Fig. 3A
We identified several enriched transcription factor-binding motifs in our TSA-treated data set by analyzing our sites with CEAS (Cis-regulatory Element Annotation System, http://ceas.cbi.pku.edu.cn), a Web-based ChIP–chip annotation system (Ji et al. 2006). TSA-treated Nup93-binding sites contained 106 enriched transcription factor-binding motifs; the top five are shown in Figure 3D Nup93 binding is proximal to differentially expressed genes We performed RNA expression analysis that revealed patterns of expression upon TSA treatment: 753 genes were induced and 828 were repressed (Supplemental Table 4). Of these genes, 91 mapped to chromosome 5 (34 induced, 57 repressed), 70 to chromosome 7 (33 induced, 37 repressed), and 29 to chromosome 16 (17 induced, 12 repressed). However, there was no obvious overlap between Nup93-binding sites and transcriptionally induced or repressed genes. To probe the relationship further, we mapped all untreated and TSA-treated Nup93-binding sites to the nearest differentially expressed gene (induced and repressed). While no distance-to-gene relationship was uncovered for untreated Nup93-binding sites (Fig. 4A
Nup93-binding sites are enriched for specific histone methylations Untreated and TSA-treated Nup93-binding sites were enriched for histone methylations associated with transcriptionally silent and active regions, respectively (Table 1). A recent study mapped 20 unique histone methylations, the histone variant H2A.Z, the insulating factor CTCF, and RNA Polymerase II (PolII) over the whole human genome (Barski et al. 2007). We compared the reported distributions of histone methylations from Barski et al. (2007) with our untreated and TSA-treated Nup93-binding sites and found several significant overlaps (Table 1). Nine of the histone modifications are associated with active genes, five with silent genes, and six showed no bias. Untreated Nup93 sites were enriched for three specific histone modifications associated with silent genes, depleted for two modifications associated with active genes, and depleted for RNA PolII-binding sites. The opposite was found with TSA-treated Nup93 sites, which were enriched for seven histone modifications associated with active genes, depleted for three modifications associated with silent genes, and enriched in RNA PolII-, H2A.Z-, and CTCF-binding sites. These results indicate that regions associated with increased transcriptional activity become associated with Nup93 upon treatment with TSA.
Nup93 association with Giemsa (G) bands To investigate chromosome-wide Nup93-binding patterns we compared the distribution of Nup93-binding sites with the G bands of chromosomes 5, 7, and 16. Staining with G dye reveals chromosome-wide banding patterns that are divided into five classes based on their staining intensity (Furey and Haussler 2003). The G-negative (Gneg) class consists of nonstaining bands, while the Gpos25, Gpos50, and Gpos75 classes contain progressively darker G-positive bands. The Gpos100 class consists of the darkest staining bands. Areas of heavy G staining represent condensed regions of the genome that have been shown to be gene poor, transcriptionally inactive, AT-rich, and replicated late in S phase. Of all the classes of G bands, Gneg bands have the highest density of genes, the largest average number of CpG islands, and are considered to represent euchromatin. We identified nonrandom distributions of Nup93 across G bands in both untreated and TSA-treated data sets when compared with chip5 distributions (Fig. 5A
Next, we investigated the distribution of Nup93-binding sites within G bands. All G bands on chromosomes 5, 7, and 16 were normalized to the same length and then partitioned into 10 sections (bins). We assigned each Nup93 site a bin (0–9) based on its relative position between its nearest G-band boundaries. For example, a Nup93-binding site at the extreme 5′ G-band boundary would be placed in bin 0, while a binding site at the extreme 3′ G-band boundary would be placed in bin 9. As a result, each bin shown in Figure 5B Discussion Our results show that the mammalian nuclear pore interacts with the human genome. To probe the functionality of this association we increased global levels of histone acetylation by treating cells with the HDAC inhibitor, TSA. Upon drug treatment, interactions between the nuclear pore and chromatin changed significantly. We observed changes in localized regions of transcriptional importance in addition to chromosome-wide changes in NPC association (Fig. 6
Local chromatin changes alter NPC association TSA treatment induces the global hyperacetylation of histones by reversibly inhibiting Class I and II HDACs. The resulting histone acetylation, which is enriched at the nuclear periphery in TSA-treated cells, decreases chromosome condensation through the recruitment of chromatin remodeling factors such as the SWI/SNF complex (Agalioti et al. 2002). Several other proteins, including CBP and the general transcription initiation factor, TFIID, are also recruited to histones through interactions with acetyl-lysine residues (Agalioti et al. 2002; Fukuda et al. 2006). Acetylated histones are typically enriched in the promoter regions of active genes and we found that Nup93 was highly enriched in these regions following TSA treatment. In addition, we identified >100 transcription factor-binding motifs in the TSA-treated Nup93-binding sites, a finding indicative of the functional repositioning of chromatin. Further evidence for a role of the mammalian nuclear transport machinery in transcriptional regulation comes from the transport protein CAS, the mammalian homolog of the yeast exportin, Cse1. A recent study has shown that CAS associates with p53 at the promoter regions of several proapoptotic genes and contributes to their transcriptional activation (Tanaka et al. 2007). Histone methylation also plays an important role in transcriptional regulation. Several H3K4 methylations are associated with actively expressed genes, while the H3K27me3 modification is associated with silent genes (Barski et al. 2007). Accordingly, Nup93-binding sites in TSA-treated cells are significantly enriched in H3K4me1–3 and depleted in H3K27me3 (Table 1). The opposite histone methylation biases are observed for untreated Nup93-binding sites, which are random with respect to H3K4me1–3 and enriched in H3K27me3. Transcriptional regulation at the NPC TSA-treated Nup93-binding sites were enriched in promoter regions and were closer to transcription start sites than their untreated counterparts. We also show that following TSA treatment, Nup93-binding sites are enriched in RNA PolII-associated regions and are closer to genes exhibiting differential expression. These regions include genes that are both highly expressed and strongly repressed following drug treatment. The presence of both active and repressed genes at nuclear pores has been observed previously in S. cerevisiae (Casolari et al. 2004). The role of the NPC as a boundary element may help explain these observations (Ishii et al. 2002). Interestingly, TSA-treated Nup93-binding sites are enriched in CTCF-associated regions. CTCF, a protein that recognizes cis-acting transcriptional insulator elements and marks histone modification boundaries (Splinter et al. 2006; Barski et al. 2007), copurifies with the histone variant H2A.Z, as well as two components of the nuclear envelope, lamin A/C and importin α3/α1 (Yusufzai et al. 2004). These associations suggest that CTCF interacts with the nuclear periphery and that regions of CTCF-mediated regulation are repositioned proximal to nuclear pores following TSA treatment. The balance of HAT and HDAC activity is essential for the maintenance of boundaries between active and repressed chromatin (Kimura et al. 2002; Suka et al. 2002). Indeed, boundary elements recruit both HATs and HDACs in order to prevent spreading of silent and active chromatin, respectively (West et al. 2004; Yusufzai et al. 2004). Mutations in HATs and HDACs can significantly shift the borders of functional regions in the genome. For example, deletion of a subunit of the Rpd3 HDAC complex in yeast leads to aberrant transcriptional initiation (Carrozza et al. 2005). The mammalian nuclear periphery contains at least one HAT and HDAC, CBP and HDAC3, respectively. CBP interacts with the NPC, while HDAC3 associates with the lamin-binding protein LAP2β. These proteins, along with CTCF, could be important components of boundary elements at the mammalian nuclear periphery. Evidence from work in S. cerevisiae has shown that recently activated genes remain at the nuclear periphery for hours after they have been repressed (Brickner et al. 2007). This localization differs from their preactivated positioning, which appears to be random with respect to the nuclear periphery (Drubin et al. 2006). This novel form of transcriptional memory is functional; it was shown that the recently repressed GAL1 gene was activated faster than a long-term repressed form. In yeast, Nup2p and the histone variant H2A.Z were involved in this process. Interestingly, we found that TSA-treated Nup93-binding sites were enriched in H2A.Z-binding sites. The presence of H2A.Z at sites of NPC–chromatin interaction could mean a similar form of transcriptional memory is present in human nuclei. Alternatively, H2A.Z site enrichment could reflect the role of this histone variant in peripherally localized boundary activity as H2A.Z has been shown to copurify with CTCF in HeLa cells and block the spread of telomeric heterochromatin in yeast (Meneghini et al. 2003; Yusufzai et al. 2004). Chromosome-wide changes in nuclear organization Large-scale changes in NPC–chromosome interactions were observed after treatment with TSA. Stretches of chromosomes 5 and 7 were no longer associated, while chromosome 16 retained the majority of its associated regions (Fig. 2A The NPC has been implicated in boundary activity in S. cerevisiae and chromosome looping is thought to occur at the nuclear periphery in Drosophila (Gerasimova et al. 2000; Ishii et al. 2002). In addition, evidence has emerged that two distally localized genes on murine chromosome 7 can be localized to the same nuclear compartment upon activation (Osborne et al. 2004). It is possible that CTCF-mediated insulator activity near mammalian NPCs could generate similar loops that functionally isolate regions of activation or repression at the nuclear periphery. Chromosome G-band patterns represent regions of genomic enrichment in either heterochromatin or euchromatin. We show that Nup93-binding sites are more likely found in heterochomatin in untreated cells, while favoring euchromatin following TSA treatment. The significant and opposing histone modifications and G-band enrichments found in Nup93-binding sites reflect a global reorganization event that exchanges silent for active chromatin at NPCs. In summary, we show that the human genome interacts with Nup93, a component of the mammalian nuclear pore. Nup93 is associated with regions of transcriptional repression and enriched heterochromatin content in HeLa cells. Upon global histone acetylation mediated by the HDAC inhibitor, TSA, Nup93 associates with regions important for transcriptional regulation. Our results hold significance for both the general mechanisms of gene expression in mammalian cells and the global effects of histone modifications on nuclear organization. Materials and methods Cell culture and drug treatment HeLa S3 cells were grown in DMEM supplemented with 10% FBS. Exponentially growing cells were incubated in the presence of 40 ng/mL TSA (Sigma) for 12 h. Cells were grown to near confluency before fixation and harvesting for ChIP–chip, indirect immunofluorescence, FISH, and expression profiling. Immunofluorescence HeLa S3 cells were grown to near confluency and adhered to polylysine-coated coverslips. Cells were prepared for labeling as described previously (Brown et al. 1996). Primary antibodies used include anti-lamin B diluted 1:50 (Santa Cruz Biotechnology), anti-Nup93 diluted 1:200 (D. Forbes), anti-acetylated H4K5 diluted 1:100 (Abcam), and anti-acetylated H3K9 diluted 1:100 (Upstate Biotechnology). Other antibodies used for preliminary ENCODE studies include anti-Nup62 (BD Transduction Laboratories), anti-Nup107, and anti-Nup205 (generous gifts from V. Cordes). The secondary antibody used to detect polyclonal primaries was goat anti-rabbit Alexa594 diluted 1:1000 (Molecular Probes). Images were acquired on a Nikon E800 epifluorescence microscope equipped with a Radiance 2000 confocal laser scanning system (Bio-Rad). FISH Bacterial artificial chromosomes (BACs) were purified using a Large-Construct Kit (Qiagen). Digoxigenin-dUTP was incorporated into purified BACs using a DIG Nick Translation Kit (Roche). For each sample, 40–160 ng of DIG-dUTP-labeled probe were combined with 40 μg of unlabeled COT1 DNA (Roche) and 20 μg of salmon sperm DNA (Ambion), a portion of which was used for hybridization. Cells were prepared and probes hybridized as described previously (Solovei et al. 2002). The probe signal was detected using an antibody enhancer kit (Roche). Vectashield containing DAPI (Vector Laboratories) was added to the slides and the coverslips were sealed with nail polish. More than 200 cells were counted for each experimental condition. FISH signal was counted as peripheral if it either overlapped with or was immediately adjacent to the nuclear periphery signal. ChIP–chip ChIP was performed essentially as described (Brodsky et al. 2005) with the following differences. Chromatin was prepared from four independently grown batches of cells—two untreated and two treated with 40 ng/mL TSA for 12 h before fixation to generate replicates for each condition. Cleared chromatin was incubated overnight with polyclonal Nup93 antibody at 4°C. After incubation, a fresh batch of 50:50 protein A/G sepharose beads were added to the chromatin/antibody solution and incubated overnight. Beads were washed five times for 10 min each, followed by DNA elution overnight, proteinase K treatment, phenol extraction, and RNase treatment. Isolated DNA was amplified isothermally using random nonamers and Klenow polymerase (Invitrogen) for 2 h, yielding ~4 μg of DNA per ChIP. DNA was prepared and hybridized to Affymetrix GeneChip Human Tiling 2.0R ChipE (chip5) arrays using fragmentation, hybridization, staining, and scanning procedures described previously (Kennedy et al. 2003). A sample of chromatin was set aside before immunoprecipitation and used to represent the input DNA. Expression profiling Total RNA was extracted with Trizol and purified with an RNeasy Mini Kit (Qiagen) with an added DNase step (RNase-free DNase; Qiagen). Fifteen micrograms of RNA from each sample were sent to the DFCI Microarray facility for labeling and hybridization to Affymetrix Human Genome U133 Plus2.0 expression arrays. Raw hybridization intensity (CEL) files from three biological replicates were processed using the RMA method (Bolstad et al. 2003; Irizarry et al. 2003a, b). Significant differentially expressed genes were considered those with average log2-transformed fold-difference ratios (TSA:Untreated) ≥1.2 or less than or equal to −1.2 and P < 0.01 (two-tailed Student’s t-test). Analysis of genomic binding data All genomic track data (sequence conservation scores, SNPs, Refseq genes, and Giemsa ideograms) were downloaded July 2006 from the University of Californai at Santa Cruz genome bioinformatics Web site (ftp://hgdownload.cse.ucsc.edu/goldenPath) for the May 2004 assembly. To maintain consistency in the track variables, these originally downloaded data were used for all subsequent analyses. Duplicate Nup93 ChIP samples were submitted to the Dana-Farber Cancer Institute Microarray Core facility for hybridization. Enrichments in ChIPs compared with input were calculated from raw intensity (CEL) files using a nonparametric statistical method implemented in Affymetrix Tiling Analysis Software (TAS) (Ghosh et al. 2006). Binding significances (expressed as probe P-values) were used to detect statistical dependencies between Nup93-binding enrichments and sequence conservation (see the Supplemental Material for a technical description of the method, including statistical significance assessment and false discovery). Acknowledgments We thank Alex Brodsky for help developing mammalian ChIP–chip; Beth Rasala for providing generous amounts of Nup93 antibody; Pamela Hollasch, Maura Berkeley, and Ed Fox at the Dana-Farber Cancer Institute’s Affymetrix Core Facility for microarray hybridization and scanning; Jennifer Waters and the Harvard Nikon Imaging Center at Harvard Medical School for help with confocal imaging; and J. Casolari, J. Hurt, and A. McKee for comments on the manuscript. This work was supported by a Ryan scholarship to C.R.B., a NIH training grant to C.J.K., and grants from the US National Institutes of Health to P.A.S. and D.J.F. Footnotes Supplemental material is available at http://www.genesdev.org. Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1632708. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
J Cell Biol. 1999 Jun 14; 145(6):1119-31.
[J Cell Biol. 1999]Trends Cell Biol. 2002 Sep; 12(9):425-32.
[Trends Cell Biol. 2002]Curr Opin Cell Biol. 2006 Jun; 18(3):307-16.
[Curr Opin Cell Biol. 2006]Science. 2003 Nov 21; 302(5649):1399-401.
[Science. 2003]Genes Dev. 1994 Jun 15; 8(12):1411-22.
[Genes Dev. 1994]Mol Cell Biol. 1994 Jan; 14(1):446-55.
[Mol Cell Biol. 1994]Genes Dev. 1996 Jul 15; 10(14):1796-811.
[Genes Dev. 1996]Genes Dev. 1996 Jun 1; 10(11):1297-309.
[Genes Dev. 1996]Nature. 1998 Aug 6; 394(6693):592-5.
[Nature. 1998]Mol Cell. 2006 Mar 17; 21(6):811-23.
[Mol Cell. 2006]EMBO J. 2007 Dec 12; 26(24):4956-65.
[EMBO J. 2007]Nature. 2006 Jun 8; 441(7094):770-3.
[Nature. 2006]Mol Cell Biol. 2006 Nov; 26(21):7858-70.
[Mol Cell Biol. 2006]Nature. 2006 Jun 8; 441(7094):774-8.
[Nature. 2006]Nat Genet. 2006 Sep; 38(9):1005-14.
[Nat Genet. 2006]J Cell Sci. 2005 Sep 1; 118(Pt 17):4017-25.
[J Cell Sci. 2005]Brief Funct Genomic Proteomic. 2006 Sep; 5(3):190-208.
[Brief Funct Genomic Proteomic. 2006]J Cell Biol. 1999 Jun 14; 145(6):1119-31.
[J Cell Biol. 1999]Hum Mol Genet. 2001 Feb 1; 10(3):211-9.
[Hum Mol Genet. 2001]Genes Dev. 2006 Jun 1; 20(11):1447-57.
[Genes Dev. 2006]Immunity. 2006 Mar; 24(3):295-304.
[Immunity. 2006]J Cell Biol. 2002 Sep 2; 158(5):915-27.
[J Cell Biol. 2002]J Cell Biol. 2000 Feb 21; 148(4):635-51.
[J Cell Biol. 2000]Mol Biol Cell. 2004 Sep; 15(9):4261-77.
[Mol Biol Cell. 2004]Mol Cell. 2006 Apr 7; 22(1):93-103.
[Mol Cell. 2006]Cell Cycle. 2006 Sep; 5(18):2146-52.
[Cell Cycle. 2006]Annu Rev Pharmacol Toxicol. 2005; 45():495-528.
[Annu Rev Pharmacol Toxicol. 2005]Nat Cell Biol. 2001 Feb; 3(2):114-20.
[Nat Cell Biol. 2001]Chromosome Res. 2004; 12(5):505-16.
[Chromosome Res. 2004]J Cell Biol. 2004 Sep 13; 166(6):815-25.
[J Cell Biol. 2004]Nat Genet. 2006 Sep; 38(9):1005-14.
[Nat Genet. 2006]Science. 2000 Dec 22; 290(5500):2306-9.
[Science. 2000]Nat Cell Biol. 2001 Feb; 3(2):114-20.
[Nat Cell Biol. 2001]Chromosome Res. 2004; 12(5):505-16.
[Chromosome Res. 2004]Nat Genet. 2006 Sep; 38(9):1005-14.
[Nat Genet. 2006]Nat Cell Biol. 2001 Feb; 3(2):114-20.
[Nat Cell Biol. 2001]Chromosome Res. 2004; 12(5):505-16.
[Chromosome Res. 2004]Genes Dev. 2002 Jan 15; 16(2):245-56.
[Genes Dev. 2002]Cell. 2005 Jul 15; 122(1):33-43.
[Cell. 2005]Nat Genet. 2006 Nov; 38(11):1289-97.
[Nat Genet. 2006]Nature. 2005 Aug 11; 436(7052):876-80.
[Nature. 2005]Hum Mol Genet. 2001 Feb 1; 10(3):211-9.
[Hum Mol Genet. 2001]Bioinformatics. 2004 Jun 12; 20(9):1464-5.
[Bioinformatics. 2004]J Cell Biol. 1999 Jun 14; 145(6):1119-31.
[J Cell Biol. 1999]J Cell Sci. 2002 Dec 1; 115(Pt 23):4597-605.
[J Cell Sci. 2002]Hum Mol Genet. 2001 Feb 1; 10(3):211-9.
[Hum Mol Genet. 2001]J Cell Biol. 2004 Sep 13; 166(6):815-25.
[J Cell Biol. 2004]Nucleic Acids Res. 2006 Jul 1; 34(Web Server issue):W551-4.
[Nucleic Acids Res. 2006]Cell. 2007 May 18; 129(4):823-37.
[Cell. 2007]Cell. 2007 May 18; 129(4):823-37.
[Cell. 2007]Hum Mol Genet. 2003 May 1; 12(9):1037-44.
[Hum Mol Genet. 2003]Cell. 2002 Nov 1; 111(3):381-92.
[Cell. 2002]Brief Funct Genomic Proteomic. 2006 Sep; 5(3):190-208.
[Brief Funct Genomic Proteomic. 2006]Cell. 2007 Aug 24; 130(4):638-50.
[Cell. 2007]Cell. 2007 May 18; 129(4):823-37.
[Cell. 2007]Cell. 2004 May 14; 117(4):427-39.
[Cell. 2004]Cell. 2002 May 31; 109(5):551-62.
[Cell. 2002]Genes Dev. 2006 Sep 1; 20(17):2349-54.
[Genes Dev. 2006]Cell. 2007 May 18; 129(4):823-37.
[Cell. 2007]Mol Cell. 2004 Jan 30; 13(2):291-8.
[Mol Cell. 2004]Nat Genet. 2002 Nov; 32(3):370-7.
[Nat Genet. 2002]Nat Genet. 2002 Nov; 32(3):378-83.
[Nat Genet. 2002]Mol Cell. 2004 Nov 5; 16(3):453-63.
[Mol Cell. 2004]Mol Cell. 2004 Jan 30; 13(2):291-8.
[Mol Cell. 2004]Cell. 2005 Nov 18; 123(4):581-92.
[Cell. 2005]PLoS Biol. 2007 Apr; 5(4):e81.
[PLoS Biol. 2007]BMC Cell Biol. 2006 Apr 24; 7():19.
[BMC Cell Biol. 2006]Cell. 2003 Mar 7; 112(5):725-36.
[Cell. 2003]Mol Cell. 2004 Jan 30; 13(2):291-8.
[Mol Cell. 2004]Mol Cell. 2000 Nov; 6(5):1025-35.
[Mol Cell. 2000]Cell. 2002 May 31; 109(5):551-62.
[Cell. 2002]Nat Genet. 2004 Oct; 36(10):1065-71.
[Nat Genet. 2004]Histochem Cell Biol. 1996 Apr; 105(4):261-7.
[Histochem Cell Biol. 1996]Genome Biol. 2005; 6(8):R64.
[Genome Biol. 2005]Nat Biotechnol. 2003 Oct; 21(10):1233-7.
[Nat Biotechnol. 2003]Bioinformatics. 2003 Jan 22; 19(2):185-93.
[Bioinformatics. 2003]BMC Bioinformatics. 2006 Oct 5; 7():434.
[BMC Bioinformatics. 2006]